Market Moves

Science Corporation raises $400 million to bring its vision implant to the US

Science Corporation’s PRIMA implant has been on sale in Europe since July for people blinded by advanced macular degeneration, and two commercial patients in Germany have now received it, Bloomberg reported. People in the United States are still waiting. On 17 November Science said it had raised $400 million, partly to change that.

The round

Science, co-founded in 2021 by former Neuralink president Max Hodak, announced a $400 million Series D with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital and Y Combinator, among others. The company says it has now raised more than $900 million since its founding.

Science did not disclose a valuation. TechCrunch and Bloomberg both reported that investors valued the company at $3.5 billion. In March, when Science raised a $230 million Series C, a source close to the company told TechCrunch that round valued it at $1.5 billion after the investment, so the reported figures put the rise at more than double in eight months.

What the money is for

Science says it will use the money to make PRIMA available in more of Europe and to prepare for a US launch through the Humanitarian Device Exemption, the FDA route for devices that treat small patient groups. It will also expand research, manufacturing and operations, and invest further in its biohybrid programme, an interface that grows engineered neurons on a device that connects to the brain’s own circuits.

PRIMA is a two-millimetre chip placed under the retina. Paired with glasses that beam images to it as near-infrared light, it restores some central vision to people blinded by geographic atrophy, the advanced form of dry age-related macular degeneration. It received its CE mark, the approval to sell across Europe, in July. Science calls it the first brain-computer interface CE marked to restore form vision, the ability to read letters, numbers and words. A company spokesperson told Bloomberg that dozens more implants are being scheduled, that Italy, France and the UK come next, and that cash-paying patients will be able to get it at Moorfields Private Eye Hospital in London.

In the final-stage PRIMAvera trial, the 18 patients still assessed for vision at three years read on average 29 more letters on an eye chart than before surgery. Those results were presented at the EURETINA congress in Vienna and have not yet been published in a journal.

The implant began in Daniel Palanker’s work at Stanford and was developed by Pixium Vision, a French company. Science bought the technology in 2024 after Pixium was placed in liquidation, and it completed the trials Pixium had started.

The road to the US

Science announced in July that PRIMA had received two Humanitarian Use Device designations from the FDA, the step before a Humanitarian Device Exemption. One covers people blinded in both eyes by advanced geographic atrophy, which the company says was approved as an “orphan subset” of a common disease. The other covers vision loss from Stargardt disease, an inherited retinal condition. Science reported its first Stargardt patient with PRIMA in October, implanted in May in a trial at Sydney Eye Hospital.

Science still needs the exemption itself before it can sell PRIMA in the US. It said in March that it had applied to the FDA, and Hodak told Bloomberg he expects PRIMA to be commercially available in the US in the first half of 2027.

The backers

Tenet Healthcare runs hospitals and outpatient surgery centres across the US, an unusual name in a brain-computer interface funding round. The Ackman Oxman Institute, the brain research institute Bill Ackman and Neri Oxman launched in August with $400 million, also co-led Precision Neuroscience’s $250 million Series D in September, so it now backs both companies. Khosla Ventures and Y Combinator also invested in Science’s Series C.

The significance of the raise

Few brain-computer interface companies have a product on sale. Science has one, and this round pays to sell it in more countries. In the US, the route it has chosen limits how many patients PRIMA can reach at a profit.

A Humanitarian Device Exemption is open only to devices for conditions affecting no more than 8,000 people a year in the US. It spares the company from proving effectiveness to the usual standard. The FDA must still find that the device will not expose patients to an unreasonable or significant risk, and that its probable benefit outweighs its risks. Once approved, it can be used only at facilities overseen by an institutional review board, a type of ethics committee.

Profit is limited too. A device approved this way can be sold for profit only if it is labelled for patients under 22 who have the condition, or if the condition occurs in adults and not in under-22s, or so rarely in them that developing the device for them is impossible, highly impracticable or unsafe. Even then, profit is allowed only up to an annual distribution number, which the FDA sets by multiplying the devices one patient needs in a year by 8,000. For a device fitted once per patient, that works out to 8,000 a year. Above that number the company can keep selling, without profit, for the rest of the year.

Not disclosed

Which investor, if any, led the round, and how much each put in. What role, if any, Tenet will play in offering PRIMA. What PRIMA costs; Science declined to give Bloomberg a price for patients at Moorfields. Whether the FDA will let Science sell PRIMA in the US for profit, and the annual number it would set. Which disease the biohybrid interface will target first; Hodak told Bloomberg the company has chosen one but not announced it.

Forward Radar: What to watch

Whether the FDA grants the exemption, and whether PRIMA reaches US patients in the first half of 2027 as Hodak expects.

PRIMA’s launch in Italy, France and the UK.

The first human test of the biohybrid interface, which Hodak told Bloomberg the company hopes to run within 16 months.

Sources

Primary:

Coverage:

Cross-reference to prior InsideBCI coverage:

Weekly BCI Brief in your inbox

Join researchers, investors, and industry leaders who start their day with Inside BCI.